These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 27775704)

  • 41. Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.
    Lin W; Huang J; Yuan Z; Feng S; Xie Y; Ma W
    Sci Rep; 2017 May; 7(1):2022. PubMed ID: 28515445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study.
    Chen Q; Wang Y; Shi S; Li K; Zhang L; Gao J
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671637
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells.
    Wang J; Anderson PD; Luo W; Gius D; Roh M; Abdulkadir SA
    Oncogene; 2012 Apr; 31(14):1794-803. PubMed ID: 21860423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
    Zhang Y; Xu B; Shi J; Li J; Lu X; Xu L; Yang H; Hamad N; Wang C; Napier D; He S; Liu C; Liu Z; Qian H; Chen L; Wei X; Zheng X; Huang JA; Thibault O; Craven R; Wei D; Pan Y; Zhou BP; Wu Y; Yang XH
    Cell Oncol (Dordr); 2020 Dec; 43(6):1049-1066. PubMed ID: 33006750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting PML in triple negative breast cancer elicits growth suppression and senescence.
    Arreal L; Piva M; Fernández S; Revandkar A; Schaub-Clerigué A; Villanueva J; Zabala-Letona A; Pujana M; Astobiza I; Cortazar AR; Hermanova I; Bozal-Basterra L; Arruabarrena-Aristorena A; Crespo JR; Valcarcel-Jimenez L; Zúñiga-García P; Canals F; Torrano V; Barrio R; Sutherland JD; Alimonti A; Martin-Martin N; Carracedo A
    Cell Death Differ; 2020 Apr; 27(4):1186-1199. PubMed ID: 31570853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.
    Song W; Hwang Y; Youngblood VM; Cook RS; Balko JM; Chen J; Brantley-Sieders DM
    Oncogene; 2017 Oct; 36(40):5620-5630. PubMed ID: 28581527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Coexistence of two quadruplex-duplex hybrids in the PIM1 gene.
    Tan DJY; Winnerdy FR; Lim KW; Phan AT
    Nucleic Acids Res; 2020 Nov; 48(19):11162-11171. PubMed ID: 32976598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
    Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
    Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics.
    Daniels VW; Zoeller JJ; van Gastel N; McQueeney KE; Parvin S; Potter DS; Fell GG; Ferreira VG; Yilma B; Gupta R; Spetz J; Bhola PD; Endress JE; Harris IS; Carrilho E; Sarosiek KA; Scadden DT; Brugge JS; Letai A
    Sci Signal; 2021 Jun; 14(686):. PubMed ID: 34103421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β.
    Fan RF; Lu Y; Fang ZG; Guo XY; Chen YX; Xu YC; Lei YM; Liu KF; Lin DJ; Liu LL; Liu XF
    Mol Med Rep; 2017 Oct; 16(4):4603-4612. PubMed ID: 28849186
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of PIM1 kinase attenuates inflammation-induced pro-labour mediators in human foetal membranes in vitro.
    Lim R; Barker G; Lappas M
    Mol Hum Reprod; 2017 Jun; 23(6):428-440. PubMed ID: 28333279
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TAB3 upregulates PIM1 expression by directly activating the TAK1-STAT3 complex to promote colorectal cancer growth.
    Li Q; Chen L; Luo C; ChenYan ; Ge J; Zhu Z; Wang K; Yu X; Lei J; Liu T; Peng X; Liu X; Yuan R
    Exp Cell Res; 2020 Jun; 391(1):111975. PubMed ID: 32229191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.
    Mahata S; Sahoo PK; Pal R; Sarkar S; Mistry T; Ghosh S; Nasare VD
    Med Oncol; 2022 May; 39(5):74. PubMed ID: 35568774
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
    Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
    Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
    [No Abstract]   [Full Text] [Related]  

  • 58. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
    Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
    Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells.
    Duan L; Tadi MJ; O'Hara KM; Maki CG
    J Biol Chem; 2024 Jun; 300(6):107375. PubMed ID: 38762181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.